Company Announcements

A&C Bio Buffer, GMP, Biomanufacturing

Aceto Acquires A&C Bio Buffer

Aceto announced today the acquisition of Limerick, Ireland based A&C Bio Buffer, a GMP (Good Manufacturing Practices) manufacturer of custom buffer and chemical blend products used in the manufacturing of biopharmaceutical drug products

See details here

 

Show More
GMP Manufacturing, CDMO, CMO, Cascade Chemistry

Aceto Acquires Cascade Chemistry

Aceto announced today the acquisition of Eugene, Oregon-based Cascade Chemistry, manufacturer of active pharmaceutical ingredients (APIs), regulatory starting materials and advanced intermediates. With this acquisition, Aceto now provides customers enhanced support throughout the drug development process and greater access to expanded North American manufacturing, particularly for APIs and advanced intermediates.

See details here

Show More
Finar Limited, Pharmaceutical Excipients

Aceto Acquires Finar Limited

May 17, 2021 - Aceto announced today the acquisition of a majority stake in Finar Limited. Finar is a leading manufacturer, supplier, and distributor of pharmaceutical excipients, lab chemicals, aquaculture inputs, and food grade additives.  The acquisition complements Aceto’s growth strategy, enhancing and expanding the company’s manufacturing footprint, R&D capabilities, and quality expertise.

 

Aceto Acquires Finar Limited

Show More
mammalian cell culture, mammalian cell culture for biopharmaceutical production, bioprocessing, cell culture media, vaccine production

Aceto Acquires A&C

Aceto Strengthens Self-Manufacturing and Vaccine and Biopharmaceutical Offering With Acquisition of A&C

 

Acquisition of A&C expands Aceto’s Western manufacturing footprint

 

 

PORT WASHINGTON, NY— April 15, 2021— Aceto, a leading global provider of specialty materials for life sciences and advanced technology end markets, announced today its acquisition of A&C, a global GMP (Good Manufacturing Practices) manufacturer of specialty excipients, buffers, and process solutions. The acquisition helps to drive Aceto’s growth strategy, increasing the company’s GMP manufacturing, packaging, and ingredients offerings for the cell culture, vaccine, and biopharmaceutical industries, while also expanding its North American footprint.

 

A&C solves customers' technical, product and regulatory challenges through GMP custom ingredient development, manufacturing, and packaging in the life science sector. With A&C, Aceto now provides customers greater access to critical raw materials and excipients used in synthesizing biologics, as well as enhanced support throughout the drug development process.

“With the acquisition of A&C, Aceto has materially expanded its self-manufactured and custom product offerings in the vaccine and biopharmaceutical space,” said Gilles Cottier, Chief Executive Officer of Aceto. “Across all of our recent acquisitions, including Syntor and IsleChem, Aceto can now offer customers an extensive selection of highest quality and competitively priced products and services to help customers secure and optimize critical supply as well as bring new products to market globally.”

 

“A&C is a service-driven organization with a mission of finding unique solutions to customers’ GMP challenges and supporting them through all stages of the development cycle,” said Ken McCracken, President & CEO of A&C. “This fundamental approach to our business perfectly aligns with Aceto’s value proposition and customer-centric service philosophy. We are excited to provide customers a differentiated, integrated suite of product offerings.”

 

Aceto will continue to support A&C’s manufacturing facilities and offices in the USA, Canada, and Ireland. Financial terms were not disclosed.

 


Show More
mammalian cell culture, mammalian cell culture for biopharmaceutical production, bioprocessing, cell culture media, vaccine production

Expanded Bioreagent Portfolio

Aceto, a leading global virtual manufacturer of specialty materials for life sciences and advanced technology end markets, announced today the introduction of an expanded portfolio for biopharmaceutical and cell culture reagent manufacturers. This offering will be built on the established expertise of Pharma Waldhof, one of Aceto’s key facilities located in Düsseldorf, Germany, developing and commercializing active ingredients, key intermediates, excipients, and reagents for multiple life science industries including pharmaceuticals, diagnostics, cosmetics, and nutrition. The Biopharma and Cell Culture portfolio will leverage Pharma Waldhof’s worldwide manufacturing and distribution capabilities, tailor-made filling and packing, and experience as a major supplier to worldwide biopharma and cell biology industries.

The Biopharma and Cell Culture offering will provide customers with access to raw materials including nucleotides, nucleosides, and bio-buffers, while also supplying cell culture media ingredients as amino acids and vitamins that further support the needs of biopharmaceutical manufacturers.

This service line expansion will provide customers greater access to raw materials and vigorously tested products for pharmaceutical cell culture applications, like ingredients for hybridoma and CHO cell culture media used in biopharmaceutical and vaccine manufacturing.

 

"Aceto is active in new product development and advanced manufacturing techniques to position the company as a preferred supplier to the highly regulated biopharma and cell culture industries," said Gilles Cottier, Chief Executive Officer of Aceto. "Using the extensive Aceto network worldwide makes it easier for customers to access their robust portfolio of products, while working with a company that is vested in its customers’ success."

Find more information here

Show More

Aceto Acquires IsleChem

Aceto Establishes Chemical Manufacturing and R&D Capabilities in the US Through Acquisition of IsleChem

Acquisition enhances Aceto’s ability to support customers through all stages of product development

 

 

PORT WASHINGTON, NY, December 21, 2020 Aceto, a leading global virtual manufacturer of specialty materials for life sciences and advanced technology end markets, announced today its acquisition of New York based, IsleChem. IsleChem’s technical, analytical and manufacturing expertise complements Aceto and expands its value-added offering to customers.

The acquisition represents an important step in Aceto’s long-term growth strategy. By adding manufacturing expertise in the U.S., Aceto builds upon its robust global supply network focused in India and China to offer access to an increasingly diversified set of products and capabilities worldwide. IsleChem’s core business includes chemical manufacturing, contract research and development (R&D), analytical services, and technical and support services, which complement Aceto’s proven leadership in chemical sourcing, quality, and supply chain. The combination of Aceto and IsleChem enhances Aceto’s established reputation for providing specialty solutions to customers around the world.

“The COVID pandemic has reinforced that access to a diverse, secure supply chain and dependable manufacturing is essential to business continuity,” said Gilles Cottier, Chief Executive Officer of Aceto. “This acquisition adds manufacturing and R&D capabilities to enhance Aceto’s already robust supply network.  IsleChem is poised for facility expansion to service growing market demand, allowing the combined company to support more of our customers’ needs from development through to commercialization and full-scale production.”

“IsleChem and Aceto share the same core value of highest quality service and both companies are intently focused on meeting the needs of our customers,” said Pat Canavan, President of IsleChem. “Joining forces gives us access to Aceto’s experienced salesforce in the U.S. and Europe, which helps us to service additional markets and enhance our value to customers.”

Aceto expects to continue to expand the workforce at IsleChem’s facility in Grand Island, NY, and bolster capabilities through additional investment in operations.

For more information regarding IsleChem, please visit IsleChem.com

Show More

Aceto Names Gilles Cottier as Chief Executive Officer and Rakesh Sachdev as Chairman

Following New Mountain Capital's growth investment into Aceto, life sciences materials veterans going to lead Aceto in its next phase of growth.

Port Washington, NY (USA) - June 20, 2019 - Aceto, a leading virtual manufacturer engaged in the development, marketing and sale of specialty materials serving the life sciences, nutrition, agricultural and advanced technology end markets, announced the appointment of Gilles Cottier as Chief Executive Officer and Rakesh Sachdev as Chairman of the Board of Directors.


“We are pleased to welcome Gilles and Rakesh to Aceto,” said Andre Moura, Managing Director at New Mountain Capital. “Gilles and Rakesh have both demonstrated an exceptional ability to understand customer need and create value for customers, employees and supplier partners within the specialty materials and life sciences industries. We look forward to working closely with Gilles and Rakesh as we invest behind a growth plan to continue Aceto’s success in the markets it serves.”


Mr. Cottier brings more than 30 years of global industry leadership experience in life sciences, fine chemicals, and research chemicals to his new role at Aceto. Most recently, he served as Head of Bioscience at Lonza. Previously, he had held numerous positions of increasing responsibility at Sigma Aldrich during his nearly 30 years there, including his role as Executive Vice President and President of the Sigma Aldrich Fine Chemicals Commercial Unit. Mr. Cottier earned a master’s degree in organic chemistry from the Ecole Supérieure de Chimie Industrielle de Lyon and the advanced management program from the Harvard Business School in Boston.


“I am excited to join Aceto, and I look forward to partnering with Aceto’s long-standing management team and associates to build on Aceto’s impressive growth track record,” said Mr. Cottier. “With its unique market presence, data resources and strong relationships, Aceto is well positioned to continue to invest in building differentiated capabilities and expanding its value proposition to customers and supplier partners.”


Mr. Sachdev recently retired as the CEO of Platform Specialty Products. Previously, he served as President and CEO of Sigma Aldrich, a global life sciences materials and technology company from 2010 to 2015, where he led the organization through its sale to Merck KGaA. Mr. Sachdev earned an M.B.A. from Indiana University, a master’s degree in Engineering from the University of Illinois, and a bachelor’s degree in Mechanical Engineering from the Indian Institute of Technology in New Delhi. He also serves as a Senior Adviser at New Mountain Capital and as a director of Avantor Inc., Element Solutions Inc., Edgewell Personal Care Company, Regal Beloit Corporation, and Washington University in St. Louis.


“Aceto is a leading player in the specialty materials and life science spaces,” said Mr. Sachdev. “Alongside New Mountain, Gilles, and the rest of the management team, I look forward to executing on a strategy to invest in key initiatives and promote accelerated growth going forward. I am thrilled to work once again with Gilles, who, at Sigma Aldrich, consistently demonstrated his outstanding ability to lead and to execute on our strategy in the life sciences and specialty materials spaces.”


About Aceto

Founded in 1947, Aceto is a leading global virtual manufacturer supplying niche, differentiated specialty materials in life sciences and advanced technology end markets. With business operations in nine countries, Aceto distributes over 1,100 chemical compounds used principally by the pharmaceutical, nutraceutical, agricultural, and specialty chemical industries. Aceto’s global operations, including a significant staff on the ground in China and India, are distinctive in the industry and enable its worldwide sourcing and regulatory capabilities.


About New Mountain Capital

New Mountain Capital is a New York based investment firm that emphasizes business building and growth, rather than debt, as it pursues long-term capital appreciation. The firm currently manages private equity, public equity, and credit funds with over $20 billion in assets under management. New Mountain seeks out what it believes to be the highest quality growth leaders in carefully selected industry sectors and then works intensively with management to build the value of these companies. For more information on New Mountain Capital, please visit www.newmountaincapital.com.


Media Contact:
Dana Gorman
Abernathy MacGregor
(212) 371-5999
dtg@abmac.com
Show More

Aceto overview by CEO Gilles Cottier

In this short video, CEO Gilles Cottier talks about Aceto, it's value to customers, how supply chain challenges are evolving for our industries, and Aceto's strategy moving forward: Video

Show More